In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Moleculin Biotech (MBRX), with a price target of $3. The company’s shares opened today at $1.27. McCarthy commented: “Following last month’s clearance to begin its European clinical trial of WP1220 (STAT3 inhibitor) in the topical treatment of cutaneous T-cell lymphoma […]

The standard joke about high-yield bonds is that they’re not high yield any longer. Let’s replace it with something better.

It’s not enough to hand over your money to the government anymore. Now you have to pay them for the privilege to do so. That’s the basic premise behind negative interest rates: investors around the world are crazy enough to buy government bonds whose yields are actually below zero. In technical terms, this GUARANTEES that […]